GSK2904545A / GSK - LARVOL DELTA

Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years (clinicaltrials.gov) - P1 | N=140 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed | N=69 ➔ 140

Enrollment change • Trial completion • Infectious Disease • CRP

Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years (clinicaltrials.gov) - P1; N=69; Active, not recruiting; Sponsor: GlaxoSmithKline; Trial primary completion date: Jul 2021 ➔ Apr 2022

Clinical • Trial primary completion date • Infectious Disease • CRP

Study of GlaxoSmithKline's (GSK) Clostridium Difficile Vaccine to Investigate the Safety and Ability to Provoke an Immune Response in the Body When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years (clinicaltrials.gov) - P1; N=69; Active, not recruiting; Sponsor: GlaxoSmithKline; Trial completion date: Jul 2021 ➔ Apr 2022

Clinical • Trial completion date • Infectious Disease • CRP

Study of GlaxoSmithKline's (GSK) Clostridium Difficile Vaccine to Investigate the Safety and Ability to Provoke an Immune Response in the Body When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years (clinicaltrials.gov) - P1; N=69; Active, not recruiting; Sponsor: GlaxoSmithKline; N=109 ➔ 69

Clinical • Enrollment change • Infectious Disease • CRP

Study of GlaxoSmithKline's (GSK) Clostridium Difficile Vaccine to Investigate the Safety and Ability to Provoke an Immune Response in the Body When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years (clinicaltrials.gov) - P1; N=109; Active, not recruiting; Sponsor: GlaxoSmithKline; N=40 ➔ 109

Clinical • Enrollment change • CRP

Study of GlaxoSmithKline's (GSK) Clostridium Difficile Vaccine to Investigate the Safety and Ability to Provoke an Immune Response in the Body When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: GlaxoSmithKline; Recruiting ➔ Active, not recruiting; N=140 ➔ 40

Clinical • Enrollment change • Enrollment closed • CRP

Study of GlaxoSmithKline's (GSK) Clostridium Difficile Vaccine to Investigate the Safety and Ability to Provoke an Immune Response in the Body When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years (clinicaltrials.gov) - P1; N=140; Recruiting; Sponsor: GlaxoSmithKline; Suspended ➔ Recruiting

Clinical • Enrollment open • CRP

Study of GlaxoSmithKline's (GSK) Clostridium Difficile Vaccine to Investigate the Safety and Ability to Provoke an Immune Response in the Body When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years (clinicaltrials.gov) - P1; N=140; Suspended; Sponsor: GlaxoSmithKline; Recruiting ➔ Suspended

Clinical • Trial suspension • CRP